Group 1: R&D Progress and Market Position - The LZM012 project has completed Phase III clinical trials for psoriasis and ankylosing spondylitis, with a formal market application expected next month for psoriasis and in the first half of next year for ankylosing spondylitis [2][3] - LZM012 is the first domestic Phase III study targeting psoriasis with PASI100 as the primary endpoint, showing superior efficacy compared to existing treatments, with fewer administration cycles and lower overall costs [2][3] - The JP-1366 tablet of the P-CAB product has been submitted for market approval, with the injection form entering Phase II clinical trials, capitalizing on the growing P-CAB market projected to reach approximately CNY 1.25 billion in 2024, an 81% year-on-year increase [3][4] Group 2: Strategic Product Development - The company is focusing on the schizophrenia long-acting injection market, with the recently approved aripiprazole microsphere being the first of its kind in China, included in the 2025 guidelines for schizophrenia treatment [4][5] - The company is advancing a new generation KCNQ2/3 activator, NS-041, which is a first-class new drug with unique molecular design, targeting both epilepsy and depression indications [5] - The company has established a comprehensive product pipeline for GnRH-a long-acting release formulations, with the approval of the first microsphere product and plans for further submissions, enhancing treatment options for various conditions [6][7] Group 3: Financial Health and Strategic Acquisitions - The company maintains a robust cash reserve, allowing for dividends, buybacks, daily operations, R&D investments, and potential strategic acquisitions [8][9] - A planned acquisition of a Vietnamese company is underway, marking the first acquisition of a Vietnamese pharmaceutical company by a Chinese enterprise, with ongoing compliance with local regulations [9] - The company aims to focus on strategic partnerships in areas such as digestion, mental health, cardiovascular, metabolic, and autoimmune diseases, targeting projects with patent barriers and commercialization potential [9]

Core Viewpoint - Lijun Group (000513) focuses on the development of microsphere technology, particularly in the areas of GnRH-α and mental health products, with significant advancements in long-acting formulations and international market expansion [1] Group 1: Product Development - The core product, Leuprolide microsphere (one-month release), is the first GnRH-α long-acting formulation approved by the FDA based on individual drug guidelines [1] - The injectable Triptorelin microsphere has received approval for prostate cancer and is expected to be approved for endometriosis in 2024, with ongoing Phase III clinical trials for central precocious puberty [1] - A three-month release Leuprolide microsphere application has been submitted, with expected approval in 2026 [1] - The company is also developing a microsphere formulation of Ganirelix, which currently has no market presence globally [1] Group 2: Mental Health Product Line - The company has launched an injectable Aripiprazole microsphere, which offers the longest dosing interval (once a month) for schizophrenia treatment globally [1] - Additional products like Brexpiprazole microsphere are in development to strengthen the long-acting product line for mental health [1] Group 3: Market Expansion in Vietnam - The acquisition of Imexpharm in Vietnam is under approval, with the company showing over 20% growth in revenue, profit, and EBITDA in the third quarter [1] - Imexpharm has the largest EU-GMP product line in Vietnam, and both companies are planning product and process transfers to leverage Imexpharm's established market channels and EU-GMP certification for expanding innovative drug products overseas [1]

Financial Performance - The company achieved a total revenue of 91.16 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 0.38% [2] - The net profit attributable to the parent company, after deducting non-recurring items, was 4.98 billion yuan, reflecting a year-on-year increase of 17.12% [2] - The formulation segment saw growth in major categories such as digestive, mental health, and traditional Chinese medicine, contributing to overall revenue stability [2] R&D Progress - The company has made significant advancements in key projects, including the submission of the P-CAB tablet for market approval and the completion of Phase II clinical trials for the injection form [3][8] - The IL-17A/F project for psoriasis and ankylosing spondylitis has completed Phase III clinical trials, with data expected to be submitted for market approval by the end of the year [4] - The NS-041 tablet for epilepsy and depression has entered Phase II clinical trials, with promising results in preclinical models [3] Market Strategy - The company plans to leverage its established sales channels in the digestive field to ensure rapid market penetration for new products like JP-1366, which is projected to achieve a sales figure of approximately 12.5 billion yuan in 2024, marking an 81% year-on-year growth [8] - The company is focusing on international expansion, particularly in Vietnam, where it aims to utilize the existing EU-GMP certified product lines of Imexpharm to enhance its market presence [6] Future Outlook - The company anticipates a stable revenue trend for the year, with profit growth expected to outpace revenue growth [11] - A clear roadmap for the launch of innovative drugs has been established, with multiple products set to enter the market over the next few years, including the IL-17A/F project and various formulations in the digestive and mental health sectors [9][10] - The company has committed to a high dividend payout, having repurchased shares worth 17.2 billion yuan and distributed nearly 60 billion yuan in dividends from 2020 to 2024 [13]